Baird's September 2026 Beauty and Wellness Quarterly puts a concrete figure on the M&A appetite sweeping the industry: 156 transactions closed in the first half of 2026, a 32% year-over-year increase. The investment bank's running tally has become the benchmark operating teams, founders and service providers use to read deal flow.

At Beauty Independent's BITE event, three specialist investors — Encore Consumer Capital, Humble Growth and True Beauty Ventures — laid out their favorite finds from the recent cohort. The session offered a working answer to a question every formulator, contract manufacturer and brand strategist is now asking: who is actually writing checks, and what are they writing them for?

How hot is the market right now?

Baird's 32% jump is the headline number, but the underlying mix matters more for trade readers. A 32% rise in transaction count typically signals a deepening of the mid-market, not just a return of mega-deals at the top of the cap table. For contract manufacturers, fragrance houses, testing labs and regulatory consultancies, a busier mid-market means more diligence projects, more product reformulations tied to owner transitions, and more distributor renegotiations as brands move between backers. The transaction density at the lower end of the market is where the operational work actually shows up.

Who's actively buying?

Encore Consumer Capital, Humble Growth and True Beauty Ventures represent three distinct theses in the consumer-investor world. Their decision to share "favorite finds" at BITE — Beauty Independent's deal-sourcing event — signals that the scouting is now public and competitive. For brands pitching capital, the trio's presence at BITE means the field of available capital is narrower than the 156-transaction headline suggests: only a subset of buyers are actively sourcing at any given time, and their stated preferences shape the bid-ask spread on every active process. Founders and intermediaries reading the market should treat public "favorite finds" lists as a signal of which categories the next round of capital is clustering around.

What are investors screening for?

Baird frames the current hunt as a search for "the next wave of category leaders," with buyers "prioritizing signs of staying" as they sort through beauty assets. For a trade audience, the screen matters. Brands built on a single hero SKU with shallow distribution score lower; multi-category platforms with documented formulation pipelines, defensible INCI stacks, repeat-purchase cohorts and retailer relationships score higher. The filter favors operators with depth, not novelty. Service providers working with targets should expect buyer diligence to focus on formulation IP, claims substantiation files and the supply agreement stack before the brand narrative.

What does this mean for product development and compliance?

Two operational consequences follow from the 32% deal growth:

• Workload for quality, regulatory and rebranding teams expands. Every closed transaction triggers label reviews, INCI list updates, claims substantiation refreshes and, in many jurisdictions, product notification updates with the relevant competent authority.
• Contract manufacturers and ingredient suppliers see more RFPs tied to owner transitions. New backers typically run a 100-day review of the cost-of-goods stack, which often surfaces reformulation candidates the prior owner never pursued.

What to watch next

Baird publishes its Beauty and Wellness Quarterly on a recurring cadence. The H2 2026 print will be the next hard data point: does the 32% H1 pace hold, or does the buyer screen narrow the field enough to slow the second half? Track the next quarterly tally, the BITE programming and the named buyers' portfolio updates for the read. The first disclosed close of an Encore Consumer Capital, Humble Growth or True Beauty Ventures BITE-flagged target will be the cleanest test of whether the public favorites list is actually a pipeline — or a marketing exercise.